Decoy Therapeutics (NASDAQ:DCOY) Raised to Hold at Wall Street Zen

Decoy Therapeutics (NASDAQ:DCOY) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other research firms also recently commented on DCOY. LADENBURG THALM/SH SH initiated coverage on Decoy Therapeutics in a report on Friday, January 23rd. They issued a “buy” rating and a $2.50 price objective for the company. Weiss Ratings initiated coverage on shares of Decoy Therapeutics in a research note on Thursday, January 22nd. They issued a “sell (e)” rating for the company. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $2.50.

Decoy Therapeutics Stock Performance

Shares of NASDAQ DCOY opened at $0.74 on Friday. The stock has a market cap of $4.74 million, a P/E ratio of -0.02 and a beta of 0.39. Decoy Therapeutics has a 12-month low of $0.51 and a 12-month high of $34.65.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.